Navigation Links
BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
Date:8/12/2009

ressions, are forward-looking statements. There are a number of important factors that could cause its actual results to differ materially from those indicated by such forward-looking statements, including the ability of its partner Auxilium to obtain regulatory approval of XIAFLEX(TM) in the United States for Dupuytren's disease and Peyronie's disease, the preparedness of Auxilium for the commercial launch of XIAFLEX(TM) for the treatment of Dupuytren's disease and the ability of Pfizer to obtain regulatory approval of XIAFLEX(TM) in its territory for these same indications, which will determine the amount of milestone, royalty and sublicense income payments it may receive; the amount of earn out payments it may receive from DFB Biotech Inc. and its affiliates; whether Auxilium exercises its option under the companies' license agreement for additional indications; the potential benefits of its existing license and development agreements; its estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company's Form 10-K for the year ended December 31, 2008 and the Form 10-Q for the quarter ended March 31, 2009 and any subsequent reports filed with the SEC. The Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

[Tables Below]

                        BIOSPECIFICS TECHNOLOGIES CORP.
                      Consolidated Statements of Operations
                                   (unaudited)

                                Three Months Ended        Six Months Ended
                                     June 30,                 June 30,
                                ------------------        -----------------
                                 2009       2008          2009         2008
                                 ----       ----   
'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioSpecifics to Present at the 9th Annual Healthcare Conference of Acumen Bio Fin Rodman Renshaw LLC
2. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
3. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
4. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
5. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
6. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
7. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
8. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
9. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
10. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
11. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares ... in its new report that the market drivers of this vibrant industry include increased ... diagnostics as part of a molecular diagnostics trend. , The global market is forecast ...
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
(Date:7/1/2015)... July 1, 2015 Isagenix International, a leading ... three Gold, three Silver, and three Bronze Stevie® Awards ... in Chicago this month.The ... business awards program in the U.S. ... strength in developing leaders, cultivating talent, creating a unified ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... in Kentucky, Indiana,Tennessee, Georgia, Alabama, Ohio and West ... Instruments Inc.,announced that it has appointed Laboratory Supply ... Tennessee, Georgia,Alabama, Ohio and West Virginia. LABSCO, the ... the United States, will sell,Nikon,s market leading i-Series ...
... innovation and product ... development for NewCardio, SANTA ... a cardiac diagnostic and services company, today,announced Dorin Panescu, PhD, ... Vice-President of Research and Development, effective,October 20. Dr. Panescu joins ...
... Glycotex, Inc. today announced,enrollment of the first patient ... GLYC-101 on wound closure and cosmetic outcomes in ... on the lower,eyelid area., A previous Phase ... of GLYC-101 at two doses compared to placebo ...
Cached Biology Technology:Nikon Instruments Appoints LABSCO its Clinical Distributor in Six States 2Dorin Panescu Named NewCardio's Chief Technical Officer 2Dorin Panescu Named NewCardio's Chief Technical Officer 3Dorin Panescu Named NewCardio's Chief Technical Officer 4Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing 2Glycotex Reports First Patient Enrollment in Phase IIb Study of Lead Product Candidate GLYC-101 for Wound Healing 3
(Date:6/16/2015)... , June 16, 2015  With the increasing ... security remains a top concern. The recent compromise of ... the need for strong authentication within government agencies. ... a biometric one-time password (OTP) authenticator, has been submitted ... (FIPS) 140-2 Level 3 validation for tamper proofing. ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue ... amount to at least 340 MSEK to that it will ... in market growth and orders received the revenue guidance for ... for 2015 will exceed 1,500 MSEK to an updated guidance ... Due to receipt of orders of touch fingerprint ...
(Date:6/15/2015)... , June 15, 2015 A new ... Telstra reveals the majority of US consumers using mobile banking ... biometrics, such as fingerprint and voiceprint, instead of having to ... According to Telstra,s " Mobile Identity   -   The ... report, with smartphones now the primary channel used by Gen ...
Breaking Biology News(10 mins):Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 2One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 3One in Four US Consumers Would Share Their DNA With Their Bank to Secure Financial and Personal Information, Telstra Report Finds 4
... researchers have played a major role in an international ... genes of 12 closely related fruit fly species. As ... genetic adaptation to evolving immune systems -- the analysis ... each species., From the results of the research, the ...
... and other morphine-like substances known as opioids, which are ... -- they may also protect you from heart attacks, ... has long been known that the so-called "runner,s high" ... exercise. However, a UI study, which is published in ...
... 300 and 600 million people in various parts of ... of the disease owing to the parasites increasing resistance ... medical treatments, with optimal limitation of resistance, requires that ... are fighting. One of the research leads involves prior ...
Cached Biology News:International team compares 12 fruit fly genomes 2International team compares 12 fruit fly genomes 3'Runner's high' may also strengthen hearts 2A genetic identity card for Plasmodium populations to improve control strategies 2A genetic identity card for Plasmodium populations to improve control strategies 3
... Recombinant Enterokinase (rEK) is a highly ... bovine enterokinase, a serine protease which recognizes ... enzyme (AspAspAspAspLys↓) and has similar enzymatic activity. ... coli and purified to yield the ...
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
... Affinity purified polyclonal antibody to the ... Goat. Isolated from a serum pool ... Salmonella. This antibody is broadly reactive ... from ATCC. It has excellent specificity ...
Features , Designed to assist users in applying domed caps to tube strips and plates , Minimises the pressure required to seal the caps effectively , Enables multiple tubes to be sealed simultaneousl...
Biology Products: